Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)

Dr. Stefano R. Tarantolo

Hematology Oncology | Oncology | Hematology
Oncology Hematology West, PC
7500 Mercy Rd, 
Omaha, NE 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Oncology Hematology West, PC
7500 Mercy Rd, 
Omaha, NE 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stefano Tarantolo is a Hematologist Oncology specialist and an Oncologist in Omaha, Nebraska. Dr. Tarantolo and is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Tarantolo is currently accepting new patients.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in NE
Hospital Affiliations
The Nebraska Methodist Hospital
Chi Health Lakeside
Chi Health St. Francis
Shenandoah Medical Center
The Nebraska Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Wellmark
  • HMO
  • POS

Locations

ONCOLOGY HEMATOLOGY WEST, PC
7500 Mercy Rd, Omaha, NE 68124
Other Locations
ONCOLOGY HEMATOLOGY WEST, PC
8303 Dodge St, Suite 250, Omaha, NE 68114
ONCOLOGY HEMATOLOGY WEST, PC
450 E 23rd St, Fremont, NE 68025
ONCOLOGY HEMATOLOGY WEST, PC
611 Fenwick Dr, Papillion, NE 68046

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Enrollment Status: Recruiting
Publish Date: July 26, 2024
Intervention Type: Drug
Study Drugs: CA-4948, Azacitidine, Venetoclax
Study Phase: Phase 1/Phase 2
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2025
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pom/Dex (Pomalidomide plus Low Dose Dexamethasone)
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cytarabine, Daunorubicin, Uproleselan
Study Phase: Phase 2/Phase 3
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: October 02, 2024
Intervention Type: Drug
Study Drugs: TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj
Study Phase: Phase 1/Phase 2
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2024
Intervention Type: Drug, Other
Study Drugs: Bosutinib, Dasatinib, Nilotinib, Nilotinib Hydrochloride Monohydrate, Ruxolitinib, Ruxolitinib Phosphate
Study Phase: Phase 2
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Enrollment Status: Completed
Publish Date: May 27, 2022
Intervention Type: Biological
Study Phase: Phase 2
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: November 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Phase II Trial Evaluating the Efficacy and Safety of Lenalidomide, Bortezomib and Dexamethasone (RVD) With or Without Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma
A Randomized, Phase II Trial Evaluating the Efficacy and Safety of Lenalidomide, Bortezomib and Dexamethasone (RVD) With or Without Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma
Enrollment Status: Terminated
Publish Date: July 24, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

9 Total Publications

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
Journal: Blood cancer journal
Published: October 03, 2022
Similar Doctors
Julie M. Vose
Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Julie M. Vose
Hematology Oncology | Hematology | Oncology
Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Julie M. Vose
Hematology Oncology | Hematology | Oncology

Unmc Physicians

111 N 175th St, 
Omaha, NE 
 (8.3 mi)
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Julie Vose is a Hematologist Oncology specialist and a Hematologist in Omaha, Nebraska. Dr. Vose and is rated as an Elite provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Her top areas of expertise are Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Vose is currently accepting new patients.

James O. Armitage
Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. James O. Armitage
Hematology Oncology | Hematology | Oncology
Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. James O. Armitage
Hematology Oncology | Hematology | Oncology

Unmc Physicians

Emile 42nd St, 
Omaha, NE 
 (3.1 mi)
402-559-4015
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients

James Armitage is a Hematologist Oncology specialist and a Hematologist in Omaha, Nebraska. Dr. Armitage and is rated as an Elite provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Peripheral T-Cell Lymphoma, Bone Marrow Transplant, and Endoscopy. Dr. Armitage is currently accepting new patients.

Matthew A. Lunning
Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Matthew A. Lunning
Oncology | Hematology
Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Matthew A. Lunning
Oncology | Hematology

Unmc Physicians

111 N 175th St, 
Omaha, NE 
 (8.3 mi)
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Lunning is an Oncologist and a Hematologist in Omaha, Nebraska. Dr. Lunning and is rated as an Elite provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Non-Hodgkin Lymphoma, T-Cell Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Lunning is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tarantolo's expertise for a condition
ConditionClose
    View All 18 Distinguished Conditions
    View All 36 Advanced Conditions
    View All 147 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile